Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?
暂无分享,去创建一个
[1] R. Samarakoon,et al. Cancer-Associated Fibroblasts: Mechanisms of Tumor Progression and Novel Therapeutic Targets , 2022, Cancers.
[2] D. Schadendorf,et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. , 2022, The New England journal of medicine.
[3] N. Lennon,et al. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. , 2022, The Lancet. Oncology.
[4] Yi Fan,et al. Vascular Microenvironment, Tumor Immunity and Immunotherapy , 2021, Frontiers in Immunology.
[5] M. Kudo,et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. , 2021, The Lancet. Oncology.
[6] Xuan Deng,et al. Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy , 2021, Frontiers in Medicine.
[7] Shaolong Zhang,et al. Crosstalk between macrophages and natural killer cells in the tumor microenvironment. , 2021, International immunopharmacology.
[8] Yuanyuan Wang,et al. Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy , 2021, Biomarker research.
[9] Parisa Sharifi,et al. Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials. , 2021, Clinical immunology.
[10] Chen Liang,et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives , 2021, Molecular Cancer.
[11] Jeremy L. Balsbaugh,et al. Lymphocyte Activation Gene-3 Regulates Dendritic Cell Metabolic Programing and T Cell Priming Function , 2021, The Journal of Immunology.
[12] S. Iacobelli,et al. Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target , 2021, Journal of translational medicine.
[13] F. Hodi,et al. Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibition. , 2021, European journal of cancer.
[14] Ruoyu Wang,et al. Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target , 2021, Journal of Hematology & Oncology.
[15] Feng Xu,et al. The CD112R/CD112 axis: a breakthrough in cancer immunotherapy , 2021, Journal of experimental & clinical cancer research : CR.
[16] R. Ferris,et al. Expression of Tim-3 drives phenotypic and functional changes in Treg cells in secondary lymphoid organs and the tumor microenvironment , 2021, Cell reports.
[17] Hua Wang,et al. Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy , 2021, Frontiers in Immunology.
[18] D. Olive,et al. BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer , 2021, Frontiers in Oncology.
[19] M. Lemmon,et al. Phosphatidylserine binding directly regulates TIM-3 function , 2021, The Biochemical journal.
[20] Fengchun Zhang,et al. Downregulation of Programmed Death-1 Pathway Promoting CD8 + T Cell Cytotoxicity in Primary Biliary Cholangitis , 2021, Digestive Diseases and Sciences.
[21] M. Peppelenbosch,et al. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer , 2021, Frontiers in Immunology.
[22] Shaoyun Cheng,et al. TIM-3: An update on immunotherapy. , 2021, International immunopharmacology.
[23] T. Kizivat,et al. Molecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: An Update , 2021, Biomedicines.
[24] J. Ahn,et al. Haemodynamic analysis of adult patients with moyamoya disease: CT perfusion and DSA gradings , 2020, Stroke and vascular neurology.
[25] V. Boussiotis,et al. The PD-1 Interactome , 2021, Advanced biology.
[26] A. Regev,et al. TIM-3 restrains anti-tumour immunity by regulating inflammasome activation , 2021, Nature.
[27] Z. Dezső,et al. VISTA is an activating receptor in human monocytes , 2021, The Journal of experimental medicine.
[28] J. Ajani,et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial , 2021, The Lancet.
[29] Y. Zhuang,et al. Activated neutrophils polarize protumorigenic interleukin‐17A‐producing T helper subsets through TNF‐α‐B7‐H2‐dependent pathway in human gastric cancer , 2021, Clinical and translational medicine.
[30] D. Munn,et al. Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma , 2021, Journal for ImmunoTherapy of Cancer.
[31] G. Mallett,et al. The depths of PD-1 function within the tumor microenvironment beyond CD8+ T cells. , 2021, Seminars in cancer biology.
[32] S. Ha,et al. Clinical Insights Into Novel Immune Checkpoint Inhibitors , 2021, Frontiers in Pharmacology.
[33] Y. Zhuang,et al. Expression, regulation and clinical significance of B7-H3 on neutrophils in human gastric cancer. , 2021, Clinical immunology.
[34] Melissa J. Davis,et al. Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent anti-tumor immunity in melanoma , 2021, Nature Immunology.
[35] B. Baradaran,et al. Interplay between MAPK/ERK signaling pathway and MicroRNAs: A crucial mechanism regulating cancer cell metabolism and tumor progression. , 2021, Life sciences.
[36] H. Xiong,et al. Roles of BTLA in Immunity and Immune Disorders , 2021, Frontiers in Immunology.
[37] M. Rosanova,et al. BRAF Gene and Melanoma: Back to the Future , 2021, International journal of molecular sciences.
[38] Ruhong Li,et al. Cancer-associated fibroblasts: overview, progress, challenges, and directions , 2021, Cancer Gene Therapy.
[39] N. Johnson,et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. , 2021, The Lancet. Oncology.
[40] P. Ascierto,et al. Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanoma , 2021, Expert opinion on emerging drugs.
[41] J. Kirkwood,et al. Beyond PD-1: The Next Frontier for Immunotherapy in Melanoma , 2021, Frontiers in Oncology.
[42] K. Mortezaee,et al. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives. , 2021, Clinical immunology.
[43] J. Jagdeo,et al. Visible Light Part I. Properties and Cutaneous Effects of Visible Light. , 2021, Journal of the American Academy of Dermatology.
[44] T. Nomura,et al. PD-L1 on mast cells suppresses effector CD8+ T-cell activation in the skin in murine contact hypersensitivity. , 2021, The Journal of allergy and clinical immunology.
[45] B. Zhu,et al. Non-canonical PD-1 signaling in cancer and its potential implications in clinic , 2021, Journal for ImmunoTherapy of Cancer.
[46] Moein Ala. The footprint of kynurenine pathway in every cancer: A new target for chemotherapy. , 2021, European journal of pharmacology.
[47] Cailin E. Joyce,et al. Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor , 2021, Oncogene.
[48] V. Steimle,et al. The MHC Class II Transactivator CIITA: Not (Quite) the Odd-One-Out Anymore among NLR Proteins , 2021, International journal of molecular sciences.
[49] Zhihai Ma,et al. CTLA-4 expression by B-1a B cells is essential for immune tolerance , 2021, Nature Communications.
[50] A. Mansfield,et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial , 2021, The Lancet.
[51] J. Becker,et al. Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy , 2021, Nature communications.
[52] M. Bros,et al. The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment , 2021, Cancers.
[53] D. DeNardo,et al. Rethinking immune checkpoint blockade: ‘Beyond the T cell’ , 2021, Journal for ImmunoTherapy of Cancer.
[54] N. Devoogdt,et al. The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time’s a Charm , 2020, International journal of molecular sciences.
[55] Sang-Hyun Hwang,et al. The BTLA and PD‐1 signaling pathways independently regulate the proliferation and cytotoxicity of human peripheral blood γδ T cells , 2020, Immunity, inflammation and disease.
[56] P. Rochaix,et al. PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells , 2020, JCI insight.
[57] D. Fisher,et al. Skin pigmentation and its control: From ultraviolet radiation to stem cells , 2020, Experimental dermatology.
[58] J. Levitt,et al. Beyond T-Cells: Functional Characterization of CTLA-4 Expression in Immune and Non-Immune Cell Types , 2020, Frontiers in Immunology.
[59] Yoon Park,et al. Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy , 2020, BMB reports.
[60] P. Gibbs,et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. , 2020, The New England journal of medicine.
[61] Qingsheng Li,et al. Anti-PD-1 antibody-mediated activation of type 17 T-cells undermines checkpoint blockade therapy , 2020, Cancer Immunology, Immunotherapy.
[62] L. Varani,et al. Ligand-Receptor Interactions of Galectin-9 and VISTA Suppress Human T Lymphocyte Cytotoxic Activity , 2020, Frontiers in Immunology.
[63] E. Engleman,et al. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. , 2020, Annual review of pathology.
[64] R. Marmorstein,et al. The MEK/ERK Network as a Therapeutic Target in Human Cancer , 2020, Molecular Cancer Research.
[65] M. Honda,et al. Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis , 2020, Journal for ImmunoTherapy of Cancer.
[66] H. Pass,et al. HMGB1 as a therapeutic target in disease , 2020, Journal of cellular physiology.
[67] N. Cross,et al. The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment , 2020, Frontiers in Immunology.
[68] A. Pitt,et al. Approaches to Investigating the Protein Interactome of PTEN. , 2020, Journal of proteome research.
[69] Yongping Song,et al. Pretreatment Peripheral B Cells Are Associated With Tumor Response to Anti-PD-1-Based Immunotherapy , 2020, Frontiers in Immunology.
[70] Sung-Bae Kim,et al. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[71] B. Seliger,et al. High PD-L1/CD274 Expression of Monocytes and Blood Dendritic Cells Is a Risk Factor in Lung Cancer Patients Undergoing Treatment with PD1 Inhibitor Therapy , 2020, Cancers.
[72] A. Zippelius,et al. Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy , 2020, Journal for ImmunoTherapy of Cancer.
[73] D. Schadendorf,et al. Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] G. Giaccone,et al. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. , 2020, The New England journal of medicine.
[75] Liping Wang,et al. Roles of IFN-γ in tumor progression and regression: a review , 2020, Biomarker research.
[76] Mingyi Chen,et al. PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade , 2020, Nature Communications.
[77] T. Powles,et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. , 2020, The Lancet. Oncology.
[78] Z. Hong,et al. TLT2 Suppresses Th1 Response by Promoting IL-6 Production in Monocyte Through JAK/STAT3 Signal Pathway in Tuberculosis , 2020, Frontiers in Immunology.
[79] V. Boussiotis,et al. Revisiting the PD-1 pathway , 2020, Science Advances.
[80] M. Hino,et al. The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphoma. , 2020, Blood advances.
[81] B. Monk,et al. LBA34 Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials , 2020, Annals of Oncology.
[82] T. Okazaki,et al. LAG-3: from molecular functions to clinical applications , 2020, Journal for ImmunoTherapy of Cancer.
[83] M. Tsuboi,et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies , 2020, Nature Immunology.
[84] Dan-yang Li,et al. ICOS+ Tregs: A Functional Subset of Tregs in Immune Diseases , 2020, Frontiers in Immunology.
[85] N. Tumino,et al. NK cells and ILCs in tumor immunotherapy. , 2020, Molecular aspects of medicine.
[86] Dakang Xu,et al. Redefining Tumor-Associated Macrophage Subpopulations and Functions in the Tumor Microenvironment , 2020, Frontiers in Immunology.
[87] Haojing Liu,et al. Tumor-associated neutrophils suppress antitumor immunity of NK cells through the PD-L1/PD-1 axis , 2020, Translational oncology.
[88] Atsushi Fujii,et al. The Expression Level of PD-L1 (CD274) mRNA in Peripheral Blood Is a Potential Biomarker for Predicting Recurrence in Breast Cancer , 2020, AntiCancer Research.
[89] K. Higuchi,et al. Increased both PD–L1 and PD–L2 expressions on monocytes of patients with hepatocellular carcinoma was associated with a poor prognosis , 2020, Scientific Reports.
[90] M. Merad,et al. PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer , 2020, Nature Cancer.
[91] S. Paik,et al. Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer , 2020, Scientific Reports.
[92] R. Jiang,et al. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma , 2020, Journal for immunotherapy of cancer.
[93] M. Galsky,et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial , 2020, The Lancet.
[94] N. Tumino,et al. Glucocorticoids and the cytokines IL-12, IL-15 and IL-18 present in the tumor microenvironment induce PD-1 expression on human Natural Killer cells. , 2020, The Journal of allergy and clinical immunology.
[95] Jifeng Yu,et al. How to select IgG subclasses in developing anti-tumor therapeutic antibodies , 2020, Journal of Hematology & Oncology.
[96] Parantu K. Shah,et al. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial , 2020, Journal for immunotherapy of cancer.
[97] M. Pistillo,et al. Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab. , 2020, Clinical immunology.
[98] C. Janse,et al. Combinatorial Tim-3 and PD-1 activity sustains antigen-specific Th1 cell numbers during blood-stage malaria. , 2020, Parasite immunology.
[99] J. Levitt,et al. MHC class I and II peptide homology regulates the cellular immune response , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[100] D. Lardinois,et al. PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade , 2020, Cancer Immunology, Immunotherapy.
[101] V. Farini,et al. Melanoma-specific bcl-2 promotes a protumoral M2-like phenotype by tumor-associated macrophages , 2020, Journal for ImmunoTherapy of Cancer.
[102] S. Balu-Iyer,et al. Biological Function and Immunotherapy Utilizing Phosphatidylserine-based Nanoparticles , 2020, Immunological investigations.
[103] M. Tambuwala,et al. Role of immune checkpoint inhibitors in the revolutionization of advanced melanoma care. , 2020, International immunopharmacology.
[104] K. Dzobo,et al. Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic. , 2020, Omics : a journal of integrative biology.
[105] Kwok-Kin Wong,et al. PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer , 2020, Nature Immunology.
[106] S. Gettinger,et al. Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer , 2020, International Journal of Cancer.
[107] D. Longo,et al. Minimal PD-1 expression in mouse and human NK cells under diverse conditions. , 2020, The Journal of clinical investigation.
[108] Z. Granot,et al. The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity in Cancer , 2020, bioRxiv.
[109] S. Warming,et al. CD96 functions as a co‐stimulatory receptor to enhance CD8+ T cell activation and effector responses , 2020, European journal of immunology.
[110] Sarah A. Middleton,et al. IgSF11 regulates osteoclast differentiation through association with the scaffold protein PSD-95 , 2020, Bone Research.
[111] Chao Cheng,et al. VISTA is a checkpoint regulator for naïve T cell quiescence and peripheral tolerance , 2020, Science.
[112] C. Berking,et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. , 2020, The Lancet. Oncology.
[113] E. Schaafsma,et al. VISTA: Coming of age as a multi‐lineage immune checkpoint , 2020, Clinical and experimental immunology.
[114] S. Leach,et al. ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity , 2020, Nature.
[115] J. Asara,et al. Targeted deletion of PD-1 in myeloid cells induces antitumor immunity , 2020, Science Immunology.
[116] S. Beissert,et al. Anti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update , 2020, Journal of clinical medicine.
[117] J. Utikal,et al. Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors , 2020, Oncoimmunology.
[118] J. Madore,et al. Tumor intrinsic and extrinsic immune functions of CD155. , 2019, Seminars in cancer biology.
[119] Y. Fujiwara,et al. Increased PD-1-positive macrophages in the tissue of gastric cancer are closely associated with poor prognosis in gastric cancer patients , 2019, BMC Cancer.
[120] Hung-Ming Wang,et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study , 2019, The Lancet.
[121] E. Schaafsma,et al. Defining the Signature of VISTA on Myeloid Cell Chemokine Responsiveness , 2019, Front. Immunol..
[122] D. Olive,et al. Role of Inducible Co-Stimulator (ICOS) in cancer immunotherapy , 2019, Expert opinion on biological therapy.
[123] Xiaozheng Xu,et al. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways. , 2019, Immunity.
[124] M. Minopoli,et al. Tumor Associated Neutrophils. Their Role in Tumorigenesis, Metastasis, Prognosis and Therapy , 2019, Front. Oncol..
[125] D. Jäger,et al. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164 , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[126] Kongming Wu,et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4 , 2019, Molecular Cancer.
[127] V. Patel,et al. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors , 2019, Journal of Immunotherapy for Cancer.
[128] Yu-Fei Lu,et al. PD1+ tumor associated macrophages predict poor prognosis of locally advanced esophageal squamous cell carcinoma. , 2019, Future oncology.
[129] R. Herbst,et al. Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy , 2019, Clinical Cancer Research.
[130] M. Moriyama,et al. CD206+ tumor-associated macrophages promote proliferation and invasion in oral squamous cell carcinoma via EGF production , 2019, Scientific Reports.
[131] S. McGregor,et al. Update on Current Treatment Recommendations for Primary Cutaneous Melanoma. , 2019, Dermatologic clinics.
[132] A. Yamniuk,et al. VISTA is an acidic pH-selective ligand for PSGL-1 , 2019, Nature.
[133] K. Syrigos,et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. , 2019, The New England journal of medicine.
[134] C. Caux,et al. Neutrophil Heterogeneity in Cancer: From Biology to Therapies , 2019, Front. Immunol..
[135] J. Machiels,et al. Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[136] Zhongchuan Wang,et al. T‐bet interferes with PD‐1/PD‐L1‐mediated suppression of CD4+ T cell inflammation and survival in Crohn's disease , 2019, Clinical and experimental pharmacology & physiology.
[137] A. Kribben,et al. BTLA Expression on Th1, Th2 and Th17 Effector T-Cells of Patients with Systemic Lupus Erythematosus Is Associated with Active Disease , 2019, International journal of molecular sciences.
[138] G. Coukos,et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance , 2019, Nature Reviews Clinical Oncology.
[139] W. Gu,et al. PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition , 2019, Front. Immunol..
[140] S. Aiba,et al. Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies , 2019, Front. Med..
[141] J. Leitner,et al. CTLA-4 antibody ipilimumab negatively affects CD4+ T-cell responses in vitro , 2019, Cancer Immunology, Immunotherapy.
[142] Huiyin Lan,et al. Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications , 2019, Journal of Hematology & Oncology.
[143] N. Cirillo,et al. Prognostic significance of CD68+ and CD163+ tumor associated macrophages in head and neck squamous cell carcinoma: A systematic review and meta-analysis. , 2019, Oral oncology.
[144] J. Ying,et al. Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer , 2019, Journal of immunotherapy.
[145] P. Ascierto,et al. Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[146] Dov A. Pechenick,et al. Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment , 2019, Cancer Immunology Research.
[147] Y. Miura,et al. Activated Fibroblast Program Orchestrates Tumor Initiation and Progression; Molecular Mechanisms and the Associated Therapeutic Strategies , 2019, International journal of molecular sciences.
[148] G. Vidarsson,et al. The Ligands for Human IgG and Their Effector Functions , 2019, Antibodies.
[149] R. Cubas,et al. Anti-PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment. , 2019, Cancer research.
[150] J. Madore,et al. CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function , 2019, Cancer Immunology Research.
[151] Yongshuai Jiang,et al. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations , 2019, Human vaccines & immunotherapeutics.
[152] Wei Zhang,et al. Disruption of CTLA-4 expression on peripheral blood CD8 + T cell enhances anti-tumor efficacy in bladder cancer , 2019, Cancer Chemotherapy and Pharmacology.
[153] S. O'Reilly,et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. , 2019, The New England journal of medicine.
[154] Bin Liu,et al. PD‐1‐expressing B cells suppress CD4+ and CD8+ T cells via PD‐1/PD‐L1‐dependent pathway , 2019, Molecular immunology.
[155] R. Schreiber,et al. Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity. , 2019, Cold Spring Harbor perspectives in biology.
[156] Y. Zhuang,et al. Increased intratumoral mast cells foster immune suppression and gastric cancer progression through TNF-α-PD-L1 pathway , 2019, Journal of Immunotherapy for Cancer.
[157] S. Ansell,et al. Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma , 2019, Blood Cancer Journal.
[158] D. Olive,et al. PD-1 is expressed by and regulates human group 3 innate lymphoid cells in human decidua , 2019, Mucosal Immunology.
[159] A. Pavlick,et al. Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma. , 2019, Future oncology.
[160] J. Wolchok,et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[161] G. Zhu,et al. Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3 , 2019, Cell.
[162] Y. Carmi,et al. Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti–PD-1 for tumor abrogation , 2018, Proceedings of the National Academy of Sciences.
[163] J. Lim,et al. Analysis of the Expression and Regulation of PD-1 Protein on the Surface of Myeloid-Derived Suppressor Cells (MDSCs) , 2018, Biomolecules & therapeutics.
[164] S. Elahi,et al. CD71+VISTA+ erythroid cells promote the development and function of regulatory T cells through TGF-β , 2018, PLoS biology.
[165] Ralph Weissleder,et al. Successful Anti‐PD‐1 Cancer Immunotherapy Requires T Cell‐Dendritic Cell Crosstalk Involving the Cytokines IFN‐&ggr; and IL‐12 , 2018, Immunity.
[166] Xiang Xu,et al. Soluble immune checkpoints in cancer: production, function and biological significance , 2018, Journal of Immunotherapy for Cancer.
[167] Qiong Sun,et al. Follicular helper T cells promote the effector functions of CD8+ T cells via the provision of IL‐21, which is downregulated due to PD‐1/PD‐L1‐mediated suppression in colorectal cancer , 2018, Experimental cell research.
[168] Maxim N. Artyomov,et al. High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy , 2018, Cell.
[169] Ming Li,et al. Myeloid cell-like transcript 2 is related to liver inflammation and the pathogenesis of hepatitis B via the involvement of CD8+T cell activation , 2018, Clinical and Experimental Medicine.
[170] G. Turcu,et al. On the Dual Role of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (CEACAM1) in Human Malignancies , 2018, Journal of immunology research.
[171] Jun Yu Li,et al. VSIG‐3 as a ligand of VISTA inhibits human T‐cell function , 2018, Immunology.
[172] S. Quezada,et al. Lost in Translation: Deciphering the Mechanism of Action of Anti-human CTLA-4 , 2018, Clinical Cancer Research.
[173] S. Elahi,et al. Lower Abundance and Impaired Function of CD71+ Erythroid Cells in Inflammatory Bowel Disease Patients During Pregnancy , 2018, Journal of Crohn's & colitis.
[174] S. Zhang,et al. Acute Myeloid Leukemia Cells Express ICOS Ligand to Promote the Expansion of Regulatory T Cells , 2018, Front. Immunol..
[175] A. Mansfield,et al. First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[176] E. Levy,et al. Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells , 2018, Front. Immunol..
[177] M. McBurney,et al. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade , 2018, The Journal of clinical investigation.
[178] Yohei Yamamoto,et al. Dual role of macrophage in tumor immunity. , 2018, Immunotherapy.
[179] Hai Qi,et al. PD-1 Controls Follicular T Helper Cell Positioning and Function , 2018, Immunity.
[180] M. Carlino,et al. Immune Checkpoint Inhibitor Toxicity , 2018, Current Oncology Reports.
[181] J. Wargo,et al. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers , 2018, Clinical Cancer Research.
[182] W. Wheat,et al. Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation , 2018, Cancer Immunology Research.
[183] S. Mineishi,et al. VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML , 2018, Oncoimmunology.
[184] S. Senju,et al. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment. , 2018, Cancer research.
[185] Kazuhiro Yoshida,et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial , 2018, The Lancet.
[186] V. Lougaris,et al. CTLA-4 regulates human Natural Killer cell effector functions. , 2018, Clinical immunology.
[187] Jonathan C. Cheng,et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 , 2018, British Journal of Cancer.
[188] Lei Wu,et al. Inhibition of SRC family kinases facilitates anti-CTLA4 immunotherapy in head and neck squamous cell carcinoma , 2018, Cellular and Molecular Life Sciences.
[189] A. Hauschild,et al. PD‐1 Blockade with Cemiplimab in Advanced Cutaneous Squamous‐Cell Carcinoma , 2018, The New England journal of medicine.
[190] E. Wherry,et al. Non-conventional Inhibitory CD4+Foxp3-PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity. , 2018, Cancer cell.
[191] R. Sullivan. The role of targeted therapy for melanoma in the immunotherapy era , 2018, Seminars in cutaneous medicine and surgery.
[192] J. Schellens,et al. Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study. , 2018 .
[193] M. Gandhi,et al. Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. , 2018, Blood.
[194] Angela E. Leek,et al. Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies , 2018, Cancer cell.
[195] C. Meisel,et al. CD96 expression determines the inflammatory potential of IL-9–producing Th9 cells , 2018, Proceedings of the National Academy of Sciences.
[196] I. Tempera,et al. Interferon-γ Signaling in Melanocytes and Melanoma Cells Regulates Expression of CTLA-4. , 2018, Cancer research.
[197] D. Sansom,et al. CTLA-4: a moving target in immunotherapy. , 2018, Blood.
[198] B. Shen,et al. Negative regulation of Nod‐like receptor protein 3 inflammasome activation by T cell Ig mucin‐3 protects against peritonitis , 2018, Immunology.
[199] R. Handgretinger,et al. Expression of checkpoint molecules on myeloid-derived suppressor cells. , 2017, Immunology letters.
[200] B. Zhang,et al. Programmed cell death‐1 (PD‐1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell–intrinsic PD‐1 , 2017, Hepatology.
[201] E. Goode,et al. IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer. , 2017, Cancer research.
[202] A. Dicker,et al. Blockade of Tumor-Expressed PD-1 promotes lung cancer growth , 2017, Oncoimmunology.
[203] A. Sharpe,et al. The diverse functions of the PD1 inhibitory pathway , 2017, Nature Reviews Immunology.
[204] T. Chan,et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab , 2017, Cell.
[205] R. Zhou,et al. Phosphatidylserine-Induced Conformational Modulation of Immune Cell Exhaustion-Associated Receptor TIM3 , 2017, Scientific Reports.
[206] J. Utikal,et al. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition. , 2017, European journal of cancer.
[207] J. Desai,et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. , 2017, The Lancet. Oncology.
[208] D. Carbone,et al. First-Line Nivolumab in Stage IV or Recurrent Non-Small Cell Lung Cancer , 2017 .
[209] C. Wellbrock,et al. PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity. , 2017, Cell reports.
[210] Qi Zhou,et al. PD-L1 Expression Promotes Epithelial to Mesenchymal Transition in Human Esophageal Cancer , 2017, Cellular Physiology and Biochemistry.
[211] Haidong Dong,et al. Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells , 2017, Front. Immunol..
[212] E. Richardsen,et al. CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases , 2017, Cancer Immunology, Immunotherapy.
[213] Y. Cheng,et al. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers , 2017, Oncogene.
[214] M. Shipp,et al. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[215] K. Flaherty,et al. An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition , 2017, The Journal of experimental medicine.
[216] Daniel M. Corey,et al. PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumor immunity , 2017, Nature.
[217] S. Held,et al. Generation and functional characterization of MDSC-like cells , 2017, Oncoimmunology.
[218] T. Janowitz,et al. A molecular and preclinical comparison of the PD-1–targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab , 2017, Seminars in oncology.
[219] Hyunjoo Lee,et al. ICOSL expression in human bone marrow-derived mesenchymal stem cells promotes induction of regulatory T cells , 2017, Scientific Reports.
[220] M. Ostrowski,et al. Tim-3 is a Marker of Plasmacytoid Dendritic Cell Dysfunction during HIV Infection and Is Associated with the Recruitment of IRF7 and p85 into Lysosomes and with the Submembrane Displacement of TLR9 , 2017, The Journal of Immunology.
[221] D. Schadendorf,et al. Immunotherapy in melanoma: Recent advances and future directions. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[222] E. Plimack,et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. , 2017, The Lancet. Oncology.
[223] S. Culine,et al. Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma , 2017, The New England journal of medicine.
[224] Q. Shao,et al. CTLA-4 positive breast cancer cells suppress dendritic cells maturation and function , 2017, Oncotarget.
[225] C. Mitchell,et al. Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatases , 2017, Bioscience reports.
[226] Xinwei Zhang,et al. PD-1 and its ligands are important immune checkpoints in cancer , 2016, Oncotarget.
[227] T. Curiel,et al. Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma. , 2016, Cancer research.
[228] J. Radford. Nivolumab for recurrent squamous-cell carcinoma of the head and neck , 2016, BDJ.
[229] A. Mansfield,et al. B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8+ T cells , 2016, Scientific Reports.
[230] K. Odunsi,et al. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer , 2016, Oncoimmunology.
[231] J. Lee,et al. The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells , 2016, Oncoimmunology.
[232] A. Chiocchetti,et al. ICOS-Ligand Triggering Impairs Osteoclast Differentiation and Function In Vitro and In Vivo , 2016, The Journal of Immunology.
[233] G. Linette,et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. , 2016, The Lancet. Oncology.
[234] K. Savage,et al. Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study , 2016, The Lancet. Oncology.
[235] D. Jäger,et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. , 2016, The Lancet. Oncology.
[236] G. Freeman,et al. Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. , 2016, Immunity.
[237] C. Berking,et al. Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab , 2016, Clinical Cancer Research.
[238] Keunchil Park,et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial , 2016, The Lancet.
[239] J. Levitt,et al. Dendritic Cell-Secreted Cytotoxic T-Lymphocyte-Associated Protein-4 Regulates the T-cell Response by Downmodulating Bystander Surface B7. , 2016, Stem cells and development.
[240] L. Bu,et al. CTLA4 blockade reduces immature myeloid cells in head and neck squamous cell carcinoma , 2016, Oncoimmunology.
[241] P. Ricciardi-Castagnoli,et al. PD-1 expression on dendritic cells suppresses CD8+ T cell function and antitumor immunity , 2016, Oncoimmunology.
[242] D. Munn,et al. IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance. , 2016, Trends in immunology.
[243] A. Moser,et al. Neocortical GABA release at high intracellular sodium and low extracellular calcium: an anti‐seizure mechanism , 2016, Journal of neurochemistry.
[244] H. Mai,et al. Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma , 2016, Oncotarget.
[245] B. Edil,et al. Br Ief Definitive Repor T Identification of Cd112r as a Novel Checkpoint for Human T Cells , 2022 .
[246] N. Gascoigne,et al. Cell Type-Specific Regulation of Immunological Synapse Dynamics by B7 Ligand Recognition , 2016, Front. Immunol..
[247] L. Jia,et al. Attenuation of the programmed cell death-1 pathway increases the M1 polarization of macrophages induced by zymosan , 2016, Cell Death and Disease.
[248] John J Miles,et al. Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy. , 2016, Cancer discovery.
[249] E. Goode,et al. PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF-κB. , 2016, Cancer research.
[250] C. Chung,et al. Enhanced Innate Inflammation Induced by Anti-BTLA Antibody in Dual Insult Model of Hemorrhagic Shock/Sepsis , 2016, Shock.
[251] Lai Wei,et al. Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma , 2015, Journal of Experimental & Clinical Cancer Research.
[252] A. Kulkarni,et al. PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma , 2015, Oncotarget.
[253] V. Kuchroo,et al. TIGIT predominantly regulates the immune response via regulatory T cells. , 2015, The Journal of clinical investigation.
[254] A. Waage,et al. PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy , 2015, PloS one.
[255] M. Valsecchi. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[256] George F. Murphy,et al. Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth , 2015, Cell.
[257] J. Utikal,et al. Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab , 2015, Clinical Cancer Research.
[258] J. Larkin,et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.
[259] Lieping Chen,et al. PD-1 Upregulated on Regulatory T Cells during Chronic Virus Infection Enhances the Suppression of CD8+ T Cell Immune Response via the Interaction with PD-L1 Expressed on CD8+ T Cells , 2015, The Journal of Immunology.
[260] J. Lunceford,et al. Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.
[261] R. Motzer,et al. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[262] G. Hämmerling,et al. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8+ T cells , 2015, Nature Immunology.
[263] G. Freeman,et al. ICOS:ICOS-ligand interaction is required for type 2 innate lymphoid cell function, homeostasis, and induction of airway hyperreactivity. , 2015, Immunity.
[264] E. Jaffee,et al. Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells , 2015, Cancer Immunology Research.
[265] D. Schadendorf,et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[266] C. Weaver,et al. PD-L1hi B cells are critical regulators of humoral immunity , 2015, Nature Communications.
[267] Ang Huang,et al. Myeloid-Derived Suppressor Cells Regulate Immune Response in Patients with Chronic Hepatitis B Virus Infection through PD-1–Induced IL-10 , 2014, The Journal of Immunology.
[268] H. Kohrt,et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.
[269] R. Emerson,et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.
[270] Hidde L. Ploegh,et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion , 2014, Nature.
[271] C. Parkinson,et al. Management of melanoma. , 2014, British medical bulletin.
[272] J. Lunceford,et al. Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. , 2014 .
[273] E. Orilieri,et al. B7h Triggering Inhibits the Migration of Tumor Cell Lines , 2014, The Journal of Immunology.
[274] P. Dessen,et al. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation , 2014, The Journal of experimental medicine.
[275] Nathalie Fiegler,et al. CTLA-4 Is Expressed by Activated Mouse NK Cells and Inhibits NK Cell IFN-γ Production in Response to Mature Dendritic Cells , 2014, The Journal of Immunology.
[276] D. Raulet,et al. NK cell self tolerance, responsiveness and missing self recognition. , 2014, Seminars in immunology.
[277] Li Zhang,et al. Cell‐extrinsic CTLA4‐mediated regulation of dendritic cell maturation depends on STAT3 , 2014, European journal of immunology.
[278] Junsang Doh,et al. Negative role of inducible PD‐1 on survival of activated dendritic cells , 2014, Journal of leukocyte biology.
[279] F. Souza-Fonseca-Guimaraes,et al. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions , 2014, Nature Immunology.
[280] Xuetao Cao,et al. Human CD14+CTLA‐4+ regulatory dendritic cells suppress T‐cell response by cytotoxic T‐lymphocyte antigen‐4‐dependent IL‐10 and indoleamine‐2,3‐dioxygenase production in hepatocellular carcinoma , 2014, Hepatology.
[281] James Legg,et al. Th1 cytokines are more effective than Th2 cytokines at licensing anti‐tumour functions in CD40‐activated human macrophages in vitro , 2014, European journal of immunology.
[282] Chunyan He,et al. Murine b7-h3 is a co-stimulatory molecule for T cell activation. , 2013, Monoclonal antibodies in immunodiagnosis and immunotherapy.
[283] T. Niki,et al. Galectin-9 prolongs the survival of septic mice by expanding tim-3-expressing natural killer T cells and PDCA-1+ CD11c+ macrophages , 2013, Critical Care.
[284] J. Haanen,et al. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[285] J. Wolchok,et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma , 2013, The Journal of experimental medicine.
[286] R. Kiessling,et al. Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid derived suppressor cells as well as their arginase1 production , 2013, Journal of Translational Medicine.
[287] J. Wolchok,et al. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4 , 2013, The Journal of experimental medicine.
[288] Hai Qi,et al. Follicular T-helper cell recruitment governed by bystander B cells and ICOS-driven motility , 2013, Nature.
[289] L. Xerri,et al. PD-1 is a novel regulator of human B-cell activation. , 2013, International immunology.
[290] A. Chiocchetti,et al. Triggering of B7h by the ICOS Modulates Maturation and Migration of Monocyte-Derived Dendritic Cells , 2013, The Journal of Immunology.
[291] Kumar Kuna,et al. Research Highlights and Editors’ Picks , 2013 .
[292] R. Locksley,et al. Innate lymphoid cells — a proposal for uniform nomenclature , 2013, Nature Reviews Immunology.
[293] J. Blay,et al. ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells. , 2012, Cancer research.
[294] Boping Zhou,et al. Tim-3-Expressing CD4+ and CD8+ T Cells in Human Tuberculosis (TB) Exhibit Polarized Effector Memory Phenotypes and Stronger Anti-TB Effector Functions , 2012, PLoS pathogens.
[295] Yuzhang Wu,et al. The Intrahepatic Expression and Distribution of BTLA and its Ligand HVEM in patients with HBV-related acute-on-chronic liver failure , 2012, Diagnostic Pathology.
[296] D. Heffernan,et al. BTLA expression contributes to septic morbidity and mortality by inducing innate inflammatory cell dysfunction , 2012, Journal of leukocyte biology.
[297] M. Maio,et al. Melanoma as a model tumour for immuno-oncology. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[298] Steffen Jung,et al. Dendritic cells ameliorate autoimmunity in the CNS by controlling the homeostasis of PD-1 receptor(+) regulatory T cells. , 2012, Immunity.
[299] M. Lotze,et al. Tumor immunity times out: TIM-3 and HMGB1 , 2012, Nature Immunology.
[300] Dennie T. Frederick,et al. Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma , 2012, Clinical Cancer Research.
[301] H. Yoshiyama,et al. Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1 , 2012, Nature Immunology.
[302] E. Abraham,et al. Identification of TLT2 as an Engulfment Receptor for Apoptotic Cells , 2012, The Journal of Immunology.
[303] Gang Li,et al. Genetic alterations of PTEN in human melanoma , 2012, Cellular and Molecular Life Sciences.
[304] A. Jha,et al. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. , 2012, Blood.
[305] T. Niki,et al. Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. , 2012, Blood.
[306] A. Stevens,et al. TNF-α and TGF-β Counter-Regulate PD-L1 Expression on Monocytes in Systemic Lupus Erythematosus , 2012, Scientific Reports.
[307] S. Rosenberg,et al. CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma , 2012, Clinical Cancer Research.
[308] Kimberly A. Thomas,et al. TLT2 Potentiates Neutrophil Antibacterial Activity and Chemotaxis in Response to G Protein-Coupled Receptor-Mediated Signaling , 2011, The Journal of Immunology.
[309] E. Goode,et al. Tumor-Infiltrating Programmed Death Receptor-1+ Dendritic Cells Mediate Immune Suppression in Ovarian Cancer , 2011, The Journal of Immunology.
[310] G. Zhu,et al. B7-h2 is a costimulatory ligand for CD28 in human. , 2011, Immunity.
[311] U. Grohmann,et al. Using an ancient tool for igniting and propagating immune tolerance: IDO as an inducer and amplifier of regulatory T cell functions. , 2011, Current medicinal chemistry.
[312] F. Carrión,et al. Opposing effect of mesenchymal stem cells on Th1 and Th17 cell polarization according to the state of CD4+ T cell activation. , 2011, Immunology letters.
[313] A. Lefvert,et al. CTLA4 is expressed on mature dendritic cells derived from human monocytes and influences their maturation and antigen presentation , 2011, BMC Immunology.
[314] David C. Gondek,et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses , 2011, The Journal of experimental medicine.
[315] P. Hwu,et al. Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells. , 2010, Cancer research.
[316] J. Weber. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade. , 2010, Seminars in oncology.
[317] M. Pistillo,et al. CTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functions. , 2010, Human immunology.
[318] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[319] M. Azuma,et al. Enhancement of effector CD8+ T‐cell function by tumour‐associated B7‐H3 and modulation of its counter‐receptor triggering receptor expressed on myeloid cell‐like transcript 2 at tumour sites , 2010, Immunology.
[320] Lieping Chen,et al. PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells , 2010, Nature Immunology.
[321] D. Douek,et al. Programmed death-1–induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection , 2010, Nature Medicine.
[322] Jessica A. Randall,et al. Correction: A Crucial Role for Kupffer Cell-Derived Galectin-9 in Regulation of T Cell Immunity in Hepatitis C Infection , 2010, PLoS ONE.
[323] Jessica A. Randall,et al. A Crucial Role for Kupffer Cell-Derived Galectin-9 in Regulation of T Cell Immunity in Hepatitis C Infection , 2010, PloS one.
[324] Y. Liu,et al. T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B. , 2010, Journal of hepatology.
[325] J. Allison,et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors , 2010, Proceedings of the National Academy of Sciences.
[326] W. Telford,et al. Regulatory T Cells and Human Myeloid Dendritic Cells Promote Tolerance via Programmed Death Ligand-1 , 2010, PLoS biology.
[327] N. Stanietsky,et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity , 2009, Proceedings of the National Academy of Sciences.
[328] L. Xerri,et al. High expression of the inhibitory receptor BTLA in T-follicular helper cells and in B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. , 2009, American journal of clinical pathology.
[329] P. Zhang,et al. Reverse signaling using an inducible costimulator to enhance immunogenic function of dendritic cells , 2009, Cellular and Molecular Life Sciences.
[330] David P. Kreil,et al. B7‐H3 is a potent inhibitor of human T‐cell activation: No evidence for B7‐H3 and TREML2 interaction , 2009, European journal of immunology.
[331] G. Zhu,et al. PD-1 on dendritic cells impedes innate immunity against bacterial infection. , 2009, Blood.
[332] T. Morio,et al. Impaired CD4 and CD8 Effector Function and Decreased Memory T Cell Populations in ICOS-Deficient Patients , 2009, The Journal of Immunology.
[333] Yuan Zhang,et al. Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells , 2009, Cancer Immunology, Immunotherapy.
[334] C. Chung,et al. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis , 2009, Proceedings of the National Academy of Sciences.
[335] C. Drake,et al. LAG-3 Regulates Plasmacytoid Dendritic Cell Homeostasis1 , 2009, The Journal of Immunology.
[336] D. Arnott,et al. B and T Lymphocyte Attenuator Regulates B Cell Receptor Signaling by Targeting Syk and BLNK , 2009, The Journal of Immunology.
[337] T. Niki,et al. Galectin-9 Increases Tim-3+ Dendritic Cells and CD8+ T Cells and Enhances Antitumor Immunity via Galectin-9-Tim-3 Interactions1 , 2008, The Journal of Immunology.
[338] H. Wiendl,et al. Human muscle cells express the costimulatory molecule B7-H3, which modulates muscle-immune interactions. , 2008, Arthritis and rheumatism.
[339] O. Fodstad,et al. The immunoregulatory protein human B7H3 is a tumor-associated antigen that regulates tumor cell migration and invasion. , 2008, Current cancer drug targets.
[340] M. Azuma,et al. Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses , 2008, Proceedings of the National Academy of Sciences.
[341] K. Murphy,et al. Regulatory T Cell Expression of Herpesvirus Entry Mediator Suppresses the Function of B and T Lymphocyte Attenuator-Positive Effector T Cells1 , 2008, The Journal of Immunology.
[342] G. Freeman,et al. ICOS/ICOSL Interaction Is Required for CD4+ Invariant NKT Cell Function and Homeostatic Survival1 , 2008, The Journal of Immunology.
[343] Peter T. White,et al. Interactions of T Cells with Fibroblast-Like Synoviocytes: Role of the B7 Family Costimulatory Ligand B7-H31 , 2008, The Journal of Immunology.
[344] C. Benedict,et al. The Inhibitory HVEM-BTLA Pathway Counter Regulates Lymphotoxin β Receptor Signaling to Achieve Homeostasis of Dendritic Cells1 , 2008, The Journal of Immunology.
[345] E. Kremmer,et al. The murine pan T cell marker CD96 is an adhesion receptor for CD155 and nectin-1. , 2007, Biochemical and biophysical research communications.
[346] E. Kremmer,et al. The adhesion receptor CD155 determines the magnitude of humoral immune responses against orally ingested antigens , 2007, European journal of immunology.
[347] G. Freeman,et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. , 2007, Immunity.
[348] U. Grohmann,et al. Immunosuppression Via Tryptophan Catabolism: The Role of Kynurenine Pathway Enzymes , 2007, Transplantation.
[349] K. Murphy,et al. Unexpected Role of B and T Lymphocyte Attenuator in Sustaining Cell Survival during Chronic Allostimulation , 2007, The Journal of Immunology.
[350] T. Chun,et al. Proliferation of activated CD1d‐restricted NKT cells is down‐modulated by lymphocyte activation gene‐3 signaling via cell cycle arrest in S phase , 2007, Cell biology international.
[351] Brantley R. Herrin,et al. Trem-Like Transcript 2 Is Expressed on Cells of the Myeloid/Granuloid and B Lymphoid Lineage and Is Up-Regulated in Response to Inflammation , 2006, The Journal of Immunology.
[352] M. van der Burg,et al. Human ICOS deficiency abrogates the germinal center reaction and provides a monogenic model for common variable immunodeficiency. , 2006, Blood.
[353] B. Kwon,et al. LIGHT enhances the bactericidal activity of human monocytes and neutrophils via HVEM , 2006, Journal of leukocyte biology.
[354] Andrea Bolognesi,et al. CTLA‐4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction , 2005, International journal of cancer.
[355] V. Kuchroo,et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity , 2005, Nature Immunology.
[356] Yusuke Nakamura,et al. Identification of immunoglobulin superfamily 11 (IGSF11) as a novel target for cancer immunotherapy of gastrointestinal and hepatocellular carcinomas , 2005, Cancer science.
[357] Malgorzata Kisielow,et al. Expression of lymphocyte activation gene 3 (LAG‐3) on B cells is induced by T cells , 2005, European journal of immunology.
[358] L. Battini,et al. Inhibitory Receptors CD85j, LAIR-1, and CD152 Down-Regulate Immunoglobulin and Cytokine Production by Human B Lymphocytes , 2005, Clinical Diagnostic Laboratory Immunology.
[359] C. Drake,et al. B and T lymphocyte attenuator exhibits structural and expression polymorphisms and is highly induced in anergic CD4+ T cells , 2005, The Journal of Immunology.
[360] C. Drake,et al. B and T Lymphocyte Attenuator Exhibits Structural and Expression Polymorphisms and Is Highly Induced in Anergic CD4+ T Cells 1 , 2005, The Journal of Immunology.
[361] E. Devilard,et al. DNAM-1 and PVR Regulate Monocyte Migration through Endothelial Junctions , 2004, The Journal of experimental medicine.
[362] J. Kaye,et al. An Inhibitory Ig Superfamily Protein Expressed by Lymphocytes and APCs Is Also an Early Marker of Thymocyte Positive Selection1 , 2004, The Journal of Immunology.
[363] In-Jeong Kim,et al. Lymphocyte Activation Gene-3 (CD223) Regulates the Size of the Expanding T Cell Population Following Antigen Activation In Vivo1 , 2004, The Journal of Immunology.
[364] M. Colonna,et al. Cutting Edge: CD96 (Tactile) Promotes NK Cell-Target Cell Adhesion by Interacting with the Poliovirus Receptor (CD155) , 2004, The Journal of Immunology.
[365] B. Kwon,et al. High levels of soluble herpes virus entry mediator in sera of patients with allergic and autoimmune diseases , 2003, Experimental & Molecular Medicine.
[366] M. Bevan,et al. B7h is required for T cell activation, differentiation, and effector function , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[367] L. Moretta,et al. Identification of PVR (CD155) and Nectin-2 (CD112) as Cell Surface Ligands for the Human DNAM-1 (CD226) Activating Molecule , 2003, The Journal of experimental medicine.
[368] M. Jordana,et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1–mediated immune responses , 2003, Nature Immunology.
[369] J. Allison,et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1 , 2003, Nature Immunology.
[370] Lieping Chen,et al. Expression of the costimulatory molecule B7-H2 (inducible costimulator ligand) by human airway epithelial cells. , 2003, American journal of respiratory cell and molecular biology.
[371] D. Vignali,et al. The CD4‐related molecule, LAG‐3 (CD223), regulates the expansion of activated T cells , 2003, European journal of immunology.
[372] A. Schäffer,et al. Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency , 2003, Nature Immunology.
[373] Y. Takai,et al. Nectin and afadin: novel organizers of intercellular junctions , 2003, Journal of Cell Science.
[374] M. J. Abedin,et al. Selective Eosinophil Adhesion to Fibroblast Via IFN-γ-Induced Galectin-9 , 2002, The Journal of Immunology.
[375] D. Pardoll,et al. Expression of Programmed Death 1 Ligands by Murine T Cells and APC1 , 2002, The Journal of Immunology.
[376] U. Grohmann,et al. CTLA-4–Ig regulates tryptophan catabolism in vivo , 2002, Nature Immunology.
[377] H. Hayasawa,et al. Molecular cloning of a novel immunoglobulin superfamily gene preferentially expressed by brain and testis. , 2002, Biochemical and biophysical research communications.
[378] G. Berry,et al. Antigen-specific regulatory T cells develop via the ICOS–ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity , 2002, Nature Medicine.
[379] H. Mages,et al. ICOS and CD28 reversely regulate IL‐10 on re‐activation of human effector T cells with mature dendritic cells , 2002, European journal of immunology.
[380] W. Sha,et al. Constitutive Expression of the B7h Ligand for Inducible Costimulator on Naive B Cells Is Extinguished after Activation by Distinct B Cell Receptor and Interleukin 4 Receptor–mediated Pathways and Can Be Rescued by CD40 Signaling , 2002, The Journal of experimental medicine.
[381] K. Sigmundsson,et al. Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Expression and Signaling in Human, Mouse, and Rat Leukocytes: Evidence for Replacement of the Short Cytoplasmic Domain Isoform by Glycosylphosphatidylinositol-Linked Proteins in Human Leukocytes1 , 2002, The Journal of Immunology.
[382] M. Gräfe,et al. ICOS-ligand, expressed on human endothelial cells, costimulates Th1 and Th2 cytokine secretion by memory CD4+ T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[383] N. Burdin,et al. Maturation and Activation of Dendritic Cells Induced by Lymphocyte Activation Gene-3 (CD223)1 , 2002, The Journal of Immunology.
[384] Tatyana Chernova,et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease , 2002, Nature.
[385] K. Ohashi,et al. Cloning and characterization of a novel mouse immunoglobulin superfamily gene expressed in early spermatogenic cells , 2001, Molecular reproduction and development.
[386] K. Shiokawa,et al. Molecular cloning and functional expression analysis of a cDNA for human hepassocin, a liver-specific protein with hepatocyte mitogenic activity. , 2001, Biochimica et biophysica acta.
[387] E. Wimmer,et al. The poliovirus receptor CD155 mediates cell-to-matrix contacts by specifically binding to vitronectin. , 2001, Virology.
[388] W. Sha,et al. Enhancement of CD8+ T Cell Responses by ICOS/B7h Costimulation1 , 2001, The Journal of Immunology.
[389] A. Houghton,et al. Immunity against cancer: lessons learned from melanoma. , 2001, Current opinion in immunology.
[390] R. Flavell,et al. Cutting Edge: Critical Role of Inducible Costimulator in Germinal Center Reactions1 , 2001, The Journal of Immunology.
[391] G. Zhu,et al. B7-H3: A costimulatory molecule for T cell activation and IFN-γ production , 2001, Nature Immunology.
[392] G. Doria,et al. Inhibition of IgG1 and IgE Production by Stimulation of the B Cell CTLA-4 Receptor1 , 2000, The Journal of Immunology.
[393] G. Freeman,et al. Mouse Inducible Costimulatory Molecule (ICOS) Expression Is Enhanced by CD28 Costimulation and Regulates Differentiation of CD4+ T Cells1 , 2000, The Journal of Immunology.
[394] D. Olive,et al. Reciprocal Expression of the TNF Family Receptor Herpes Virus Entry Mediator and Its Ligand LIGHT on Activated T Cells: LIGHT Down-Regulates Its Own Receptor1 , 2000, The Journal of Immunology.
[395] P. Anderson,et al. Modification of P-selectin glycoprotein ligand-1 with a natural killer cell-restricted sulfated lactosamine creates an alternate ligand for L-selectin. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[396] I. Scheffrahn,et al. The tumor growth-inhibiting cell adhesion molecule CEACAM1 (C-CAM) is differently expressed in proliferating and quiescent epithelial cells and regulates cell proliferation. , 2000, Cancer research.
[397] Paul W. Wu,et al. Cutting Edge: Identification of GL50, a Novel B7-Like Protein That Functionally Binds to ICOS Receptor , 2000, The Journal of Immunology.
[398] S. Ergün,et al. CEA-related cell adhesion molecule 1: a potent angiogenic factor and a major effector of vascular endothelial growth factor. , 2000, Molecular cell.
[399] P. Valent,et al. Expression of homing receptors and related molecules on human mast cells and basophils: a comparative analysis using multi-color flow cytometry and toluidine blue/immunofluorescence staining techniques. , 1999, Tissue antigens.
[400] M. Avice,et al. Lymphocyte activation gene-3, a MHC class II ligand expressed on activated T cells, stimulates TNF-alpha and IL-12 production by monocytes and dendritic cells. , 1999, Journal of immunology.
[401] T. Honjo,et al. Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. , 1998, International immunology.
[402] B. Maigret,et al. Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[403] C. Benoist,et al. Independent Modes of Natural Killing Distinguished in Mice Lacking Lag3 , 1996, Science.
[404] P. Bruggen,et al. Human tumor antigens recognized by T lymphocytes , 1996, The Journal of experimental medicine.
[405] J. Bluestone,et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. , 1995, Immunity.
[406] G. Vachino,et al. P-selectin Glycoprotein Ligand-1 Is the Major Counter-receptor for P-selectin on Stimulated T Cells and Is Widely Distributed in Non-functional Form on Many Lymphocytic Cells * , 1995, The Journal of Biological Chemistry.
[407] P. Linsley,et al. Activated T cells can induce high levels of CTLA-4 expression on B cells. , 1995, Journal of immunology.
[408] R. Cummings,et al. The P-selectin glycoprotein ligand from human neutrophils displays sialylated, fucosylated, O-linked poly-N-acetyllactosamine. , 1994, The Journal of biological chemistry.
[409] S. Roman-Roman,et al. LAG-3, a novel lymphocyte activation gene closely related to CD4 , 1990, The Journal of experimental medicine.
[410] Jie Xu,et al. Molecular and Cellular Functions of CTLA-4. , 2020, Advances in experimental medicine and biology.
[411] Jie Xu,et al. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond. , 2020, Advances in experimental medicine and biology.
[412] D. Schadendorf,et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. , 2019, The New England journal of medicine.
[413] M. Caligiuri,et al. The mechanism of anti-PD-L1 antibody efficacy against PD-L1 negative tumors identifies NK cells expressing PD-L1 as a cytolytic effector. , 2019, Cancer discovery.
[414] F. Garrido. MHC/HLA Class I Loss in Cancer Cells. , 2019, Advances in experimental medicine and biology.
[415] K. Fujio,et al. Overview of LAG-3-Expressing, IL-10-Producing Regulatory T Cells. , 2017, Current topics in microbiology and immunology.
[416] D. Olive,et al. Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization , 2017, The Journal of allergy and clinical immunology.
[417] Tim K. Lee,et al. Melanoma Epidemiology and Prevention. , 2016, Cancer treatment and research.
[418] A. Eljaszewicz,et al. Prognostic significance of PD-1 expression on peripheral blood CD4+ T cells in patients with newly diagnosed chronic lymphocytic leukemia. , 2015, Polskie Archiwum Medycyny Wewnetrznej.
[419] P. Zigrino,et al. Metalloproteinases in melanoma. , 2014, European journal of cell biology.
[420] Y. Tüzün,et al. Basic histological structure and functions of facial skin. , 2014, Clinics in dermatology.
[421] T. Matsuo,et al. TNFSF14 coordinately enhances CXCL10 and CXCL11 productions from IFN-gamma-stimulated human gingival fibroblasts. , 2010, Molecular immunology.
[422] F. Hodi,et al. Tumor and Stem Cell Biology Cancer Research Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells , 2010 .
[423] H. Clark,et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells , 2009, Nature Immunology.
[424] 永原 慶子. Galectin-9 increases Tim-3[+] dendritic cells and CD8[+] T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions , 2009 .
[425] K. Akiyama,et al. Expression and Function of the Inducible Costimulator Ligand B 7-H 2 in Human Airway Smooth Muscle Cells , 2008 .
[426] M. Lotze,et al. Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors. , 2007, Journal of immunotherapy.
[427] L. Moretta,et al. Identification of PVR ( CD 155 ) and Nectin-2 ( CD 112 ) as Cell Surface Ligands for the Human DNAM-1 ( CD 226 ) Activating Molecule , 2003 .
[428] S. Yagihashi,et al. Interferon-gamma stimulates the expression of galectin-9 in cultured human endothelial cells. , 2002, Journal of leukocyte biology.
[429] M. Ohkawa,et al. Selective eosinophil adhesion to fibroblast via IFN-gamma-induced galectin-9. , 2002, Journal of immunology.
[430] G. Zhu,et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. , 2001, Nature immunology.
[431] G. Zhu,et al. Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS. , 2000, Blood.